Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

ANRO

Alto Neuroscience (ANRO)

Alto Neuroscience Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:ANRO
DataHoraFonteTítuloCódigoCompanhia
20/06/202409:05Business WireAlto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with SchizophreniaNYSE:ANROAlto Neuroscience Inc
18/06/202409:05Business WireAmit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award WinnerNYSE:ANROAlto Neuroscience Inc
29/05/202409:05Business WireAlto Neuroscience to Present at the Jefferies Global Healthcare ConferenceNYSE:ANROAlto Neuroscience Inc
21/05/202409:29Edgar (US Regulatory)Form 8-K - Current reportNYSE:ANROAlto Neuroscience Inc
21/05/202409:05Business WireAlto Neuroscience Appoints Michael Hanley as Chief Operating OfficerNYSE:ANROAlto Neuroscience Inc
14/05/202417:32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ANROAlto Neuroscience Inc
14/05/202417:03Business WireAlto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business HighlightsNYSE:ANROAlto Neuroscience Inc
09/05/202409:05Business WireAlto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific ConferencesNYSE:ANROAlto Neuroscience Inc
23/04/202409:05Business WireAlto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for SchizophreniaNYSE:ANROAlto Neuroscience Inc
03/04/202409:05Business WireAlto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderNYSE:ANROAlto Neuroscience Inc
21/03/202417:05Business WireAlto Neuroscience Reports Full Year 2023 Financial Results and Recent Business HighlightsNYSE:ANROAlto Neuroscience Inc
11/03/202409:05Business WireAlto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of DirectorsNYSE:ANROAlto Neuroscience Inc
07/03/202410:00Business WireAlto Neuroscience to Participate in Upcoming Investor ConferencesNYSE:ANROAlto Neuroscience Inc
27/02/202410:00Business WireAlto Neuroscience to Present at the TD Cowen 44th Annual Healthcare ConferenceNYSE:ANROAlto Neuroscience Inc
06/02/202418:05Business WireAlto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNYSE:ANROAlto Neuroscience Inc
 Apresentando as notícias mais relevantes sobre:NYSE:ANRO